Lifecore Biomedical, Inc.

Equities

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.17 USD +0.19% Intraday chart for Lifecore Biomedical, Inc. +3.19% -16.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024 MT
Top Midday Decliners MT
Lifecore Biomedical Charts Standalone Path, Names Paul Josephs as New CEO Amid Board Changes MT
Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024 CI
Lifecore Biomedical, Inc. Announces Management Changes CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia... Our Logo
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Sector Update: Health Care MT
Lifecore Biomedical Shares Rise Following Expansion of Alcon Contract MT
Alcon, Lifecore Biomedical Extend Contract Manufacturing Agreement MT
Lifecore Biomedical Remains Actively Engaged in its Evaluation of Potential Strategic Alternatives CI
Lifecore Biomedical, Inc. Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements CI
North American Morning Briefing : Geopolitical -2- DJ
Lifecore Biomedical Enters Into Co-Marketing Partnership With SHL Medical MT
SHL Medical and Lifecore Biomedical Enter Co-Marketing Partnership Agreement CI
North American Morning Briefing : Stock Futures -2- DJ
Lifecore Biomedical Releases Update on Timing of Delayed Filings, Development Portfolio MT
North American Morning Briefing : S&P 500 Futures -2- DJ
Stephens Adjusts Price Target on Lifecore Biomedical to $9 From $8, Maintains Equalweight Rating MT
Barrington Trims Price Target on Lifecore Biomedical to $10 From $11, Maintains Outperform Rating MT
Earnings Flash (LFCR) LIFECORE BIOMEDICAL Reports Q4 Revenue $31.5M MT
Transcript : Lifecore Biomedical, Inc., Q4 2023 Earnings Call, Aug 31, 2023
Lifecore Biomedical, Inc. Reports Earnings Results for the Full Year Ended May 28, 2023 CI
Lifecore Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended May 28, 2023 CI
North American Morning Briefing : PCE Inflation -2- DJ
Chart Lifecore Biomedical, Inc.
More charts
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company and its subsidiaries design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners. The Company specializes in specialty formulation, aseptic filling, and final packaging of both complex medical devices and injectable pharmaceuticals. It manufactures commercial products at its three cGMP facilities. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a broad spectrum of medical conditions and procedures. It sells products utilizing hyaluronan that is distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.17 USD
Average target price
8 USD
Spread / Average Target
+54.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Lifecore Biomedical, Inc. - Nasdaq
  4. News Lifecore Biomedical, Inc.
  5. Landec : Earnings Flash (LNDC) LANDEC CORPORATION Posts Q3 Loss $-0.09, vs. Street Est of $0.04